616 related articles for article (PubMed ID: 15623441)
21. Comparison of MR imaging and FDG-PET/CT in the differential diagnosis of benign and malignant vertebral compression fractures.
Cho WI; Chang UK
J Neurosurg Spine; 2011 Feb; 14(2):177-83. PubMed ID: 21214309
[TBL] [Abstract][Full Text] [Related]
22. Searching for indicators of malignancy in pancreatic intraductal papillary mucinous neoplasms: the value of 18FDG-PET confirmed.
Baiocchi GL; Bertagna F; Gheza F; Grazioli L; Calanducci D; Giubbini R; Portolani N; Giulini SM
Ann Surg Oncol; 2012 Oct; 19(11):3574-80. PubMed ID: 22752369
[TBL] [Abstract][Full Text] [Related]
23. The utility of F-18 fluorodeoxyglucose whole body PET imaging for determining malignancy in cystic lesions of the pancreas.
Mansour JC; Schwartz L; Pandit-Taskar N; D'Angelica M; Fong Y; Larson SM; Brennan MF; Allen PJ
J Gastrointest Surg; 2006 Dec; 10(10):1354-60. PubMed ID: 17175454
[TBL] [Abstract][Full Text] [Related]
24. Role of SUV(max) obtained by 18F-FDG PET/CT in patients with a solitary pancreatic lesion: predicting malignant potential and proliferation.
Hu SL; Yang ZY; Zhou ZR; Yu XJ; Ping B; Zhang YJ
Nucl Med Commun; 2013 Jun; 34(6):533-9. PubMed ID: 23503000
[TBL] [Abstract][Full Text] [Related]
25. Solid splenic masses: evaluation with 18F-FDG PET/CT.
Metser U; Miller E; Kessler A; Lerman H; Lievshitz G; Oren R; Even-Sapir E
J Nucl Med; 2005 Jan; 46(1):52-9. PubMed ID: 15632034
[TBL] [Abstract][Full Text] [Related]
26. Hyperaccumulation of (18)F-FDG in order to differentiate solid pseudopapillary tumors from adenocarcinomas and from neuroendocrine pancreatic tumors and review of the literature.
Guan ZW; Xu BX; Wang RM; Sun L; Tian JH
Hell J Nucl Med; 2013; 16(2):97-102. PubMed ID: 23687644
[TBL] [Abstract][Full Text] [Related]
27. [The application of 18F-fluorodeoxyglucose positron emission tomography in the diagnosis and staging of lung cancer].
Xu HF; Liu Y; Zhang JH; Zhou RS; Zhou FH; Yuan MH
Zhonghua Jie He He Hu Xi Za Zhi; 2005 Feb; 28(2):108-11. PubMed ID: 15854393
[TBL] [Abstract][Full Text] [Related]
28. Diagnosis of pancreatic carcinoma: role of FDG PET.
Keogan MT; Tyler D; Clark L; Branch MS; McDermott VG; DeLong DM; Coleman RE
AJR Am J Roentgenol; 1998 Dec; 171(6):1565-70. PubMed ID: 9843289
[TBL] [Abstract][Full Text] [Related]
29. Clinical value of F18-fluorodeoxyglucose positron emission tomography-computed tomography in patients with non-small cell lung cancer after potentially curative surgery: experience with 241 patients.
Kanzaki R; Higashiyama M; Maeda J; Okami J; Hosoki T; Hasegawa Y; Takami M; Kodama K
Interact Cardiovasc Thorac Surg; 2010 Jun; 10(6):1009-14. PubMed ID: 20197344
[TBL] [Abstract][Full Text] [Related]
30. The value of
Regenet N; Sauvanet A; Muscari F; Meunier B; Mariette C; Adham M; Moutardier V; Delpero JR; Regimbeau JM; Pessaux P; Paye F; Sa Cunha A; Ansquer C
J Visc Surg; 2020 Oct; 157(5):387-394. PubMed ID: 32005594
[TBL] [Abstract][Full Text] [Related]
31. Clinical usefulness of 18-fluorodeoxyglucose positron emission tomography in the management of patients with nonpancreatic periampullary neoplasms.
Sperti C; Pasquali C; Fiore V; Bissoli S; Chierichetti F; Liessi G; Pedrazzoli S
Am J Surg; 2006 Jun; 191(6):743-8. PubMed ID: 16720142
[TBL] [Abstract][Full Text] [Related]
32. Differentiation of malignant and benign cardiac tumors using 18F-FDG PET/CT.
Rahbar K; Seifarth H; Schäfers M; Stegger L; Hoffmeier A; Spieker T; Tiemann K; Maintz D; Scheld HH; Schober O; Weckesser M
J Nucl Med; 2012 Jun; 53(6):856-63. PubMed ID: 22577239
[TBL] [Abstract][Full Text] [Related]
33. Imaging of indeterminate pancreatic cystic lesions: a systematic review.
Jones MJ; Buchanan AS; Neal CP; Dennison AR; Metcalfe MS; Garcea G
Pancreatology; 2013; 13(4):436-42. PubMed ID: 23890144
[TBL] [Abstract][Full Text] [Related]
34. Focal thyroid lesions incidentally identified by integrated 18F-FDG PET/CT: clinical significance and improved characterization.
Choi JY; Lee KS; Kim HJ; Shim YM; Kwon OJ; Park K; Baek CH; Chung JH; Lee KH; Kim BT
J Nucl Med; 2006 Apr; 47(4):609-15. PubMed ID: 16595494
[TBL] [Abstract][Full Text] [Related]
35.
Abadi P; Johansen A; Godballe C; Gerke O; Høilund-Carlsen PF; Thomassen A
Ann Nucl Med; 2017 Feb; 31(2):101-108. PubMed ID: 27921286
[TBL] [Abstract][Full Text] [Related]
36. The clinical usefulness of 18-fluorodeoxyglucose positron emission tomography in the differential diagnosis, staging, and response evaluation after concurrent chemoradiotherapy for pancreatic cancer.
Bang S; Chung HW; Park SW; Chung JB; Yun M; Lee JD; Song SY
J Clin Gastroenterol; 2006; 40(10):923-9. PubMed ID: 17063113
[TBL] [Abstract][Full Text] [Related]
37. Additional value of FDG PET/CT to contrast-enhanced CT in the differentiation between benign and malignant intraductal papillary mucinous neoplasms of the pancreas with mural nodules.
Takanami K; Hiraide T; Tsuda M; Nakamura Y; Kaneta T; Takase K; Fukuda H; Takahashi S
Ann Nucl Med; 2011 Aug; 25(7):501-10. PubMed ID: 21537945
[TBL] [Abstract][Full Text] [Related]
38. FLT PET/CT Is Better Than FDG PET/CT in Differentiating Benign From Malignant Pancreatobiliary Lesions.
Vineeth Kumar PM; Verma GR; Mittal BR; Agrawal K; Gupta R; Kochhar R; Singh V; Kaman L; Singh R
Clin Nucl Med; 2016 May; 41(5):e244-50. PubMed ID: 26914562
[TBL] [Abstract][Full Text] [Related]
39. Comparison of International Consensus Guidelines versus 18-FDG PET in detecting malignancy of intraductal papillary mucinous neoplasms of the pancreas.
Pedrazzoli S; Sperti C; Pasquali C; Bissoli S; Chierichetti F
Ann Surg; 2011 Dec; 254(6):971-6. PubMed ID: 22076067
[TBL] [Abstract][Full Text] [Related]
40. Usefulness of positron emission tomography (PET)/contrast-enhanced computed tomography (CE-CT) in discriminating between malignant and benign intraductal papillary mucinous neoplasms (IPMNs).
Ohta K; Tanada M; Sugawara Y; Teramoto N; Iguchi H
Pancreatology; 2017; 17(6):911-919. PubMed ID: 29033011
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
